Bristol partners with Gilead to develop once-daily HIV drug combo

10/26/2011 | Yahoo!

Bristol-Myers Squibb signed a licensing agreement to develop a once-daily HIV tablet that would combine the firm's protease inhibitor Reyataz and Gilead Sciences' experimental booster cobicistat. Gilead began Phase II and III tests on newly diagnosed patients. If the combination therapy is commercialized, Bristol will pay Gilead royalties.

View Full Article in:


Published in Briefs: